A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A phase 2 trial of Venetoclax in chronic lymphocytic leukaemia, run by AbbVie, active and no longer recruiting.
Overview
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma is a phase 2 interventional study registered as NCT02966756 by AbbVie, with 66 participants enrolled, started 2017-10-12 and due to reach its primary completion in 2030-12. Interventions recorded: Venetoclax.
Similar pages
not linked directly; found by shared links- TrialStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Shares AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Shares AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Shares AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialPhase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Shares AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialIMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Shares AbbVie (incl. ImmunoGen, Capstan), Venetoclax and the tag pipeline.
- TrialA Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Shares AbbVie (incl. ImmunoGen, Capstan), Venetoclax and the tag pipeline.
- TrialA Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Shares Chronic lymphocytic leukaemia and the tag pipeline.